We investigated immediate immunization pain in 12-month-old children randomized to receive a booster dose of either the 10- (PCV-10) or the 13-valent (PCV-13) pneumococcal conjugate vaccine. Pain was assessed using validated pain assessment tools and crying time. PCV-13 recipients had significantly higher scores on the observer-rated modified behavioral pain scale than did those receiving PCV-10, but the differences were small.Clinical trial registration at Clinicaltrials.gov (NCT01443416).

Original publication

DOI

10.1097/inf.0000000000001894

Type

Journal article

Journal

The Pediatric infectious disease journal

Publication Date

10/01/2018

Addresses

Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.